| Old Articles: <Older 6761-6770 Newer> |
|---|
 |
The Motley Fool
October 11, 2010
Travis Hoium |
AOB Shares Popped: What You Need to Know Shares of American Oriental Bioengineering rose 10% in intraday trading on unusually high volumes.   |
The Motley Fool
October 11, 2010
Travis Hoium |
GNBT Shares Popped Then Plunged: What You Need to Know Generex Biotechnology Corp shares rose 25% in early market trading before falling on news the company will acquire a 51% stake in Global Medical Direct. |
The Motley Fool
October 11, 2010
Travis Hoium |
Alexza Shares Plunged: What You Need to Know Alexza Pharmaceuticals shares fell 52% today after the Food and Drug Administration did not clear the company's new drug, AZ-004. |
The Motley Fool
October 11, 2010
Brian Orelli |
What Meridia's Demise Means for Arena, VIVUS, and Orexigen Safety first ... and second ... and third... |
Chemistry World
October 8, 2010
Sarah Houlton |
U-turn on Alzheimer's drugs in the UK The UK National Institute for Health and Clinical Excellence proposes that those with mild disease will be able to receive them from early next year, on the basis of growing clinical evidence of their effectiveness. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Bristol-Myers Almost Ready to Seal the Deal With ZymoGenetics ZymoGenetics, one of the driving forces of Seattle biotech the past 30 years, is about to become a thing of the past. |
The Motley Fool
October 8, 2010
Brian D. Pacampara |
Neurocrine Popped: What You Need to Know While the possibility of a big return exists, know that Neurocrine, as is the case with all baby biotechs, can plunge just as hard. |
The Motley Fool
October 8, 2010
Luke Timmerman |
Onyx Delays Cancer Drug Application As FDA Asks for More Data Shares fell about 7% in after-hours trading Thursday evening. |
BusinessWeek
October 7, 2010
Olga Kharif |
Eyeglass Innovator: Ronald Blum Optometrist Ronald Blum says his electronic eyeglasses improve on bifocals and progressive lenses, which cause nausea and headaches for some wearers. |
| <Older 6761-6770 Newer> Return to current articles. |
